A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Clinical trial NCT05910827 · RECRUITING

Trial details

NCT number: NCT05910827
Sponsor: Hummingbird Bioscience
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Advanced Head and Neck Squamous Cell Carcinoma Advanced Esophageal Squamous Cell Carcinoma Cervical Squamous Cell Carcinoma Advanced Cutaneous Squamous Cell Carcinoma Nasopharyngeal Cancinoma (NPC)Squamous Cell Carcinoma

Start date: 2024-02-05
Primary completion: 2027-12-01
Enrollment: 398

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.